Skip to content | Change text size
 

William N. Charman

Photo of Prof Charman

Professor of Pharmaceutics
Director, Centre for Drug Candidate Optimisation

BPharm, VCP; PhD, Univ. Kansas

Phone: +61 3 9903 9519
Fax: +61 3 9903 9560
email: Bill.Charman@pharm.monash.edu.au

General research interests

  • Oral drug delivery and lymphatic drug transport
  • Lipid-based formulation design and assessment
  • Drug discovery and lead optimisation

Current research areas

  • Design of formulations to enhance oral drug bioavailability
  • Mechanistic evaluation of intestinal lymphatic drug transport
  • Design, lead optimisation and pre-clinical development of new drug candidates
  • Development of new methods for supporting rapid throughput lead optimisation

Recent significant publications

  1. S.A. Charman, C. Perry, F. Chiu, K. McIntosh, R. Prankerd, W.N. Charman.  Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. (2006) Journal of Pharmaceutical Sciences 95(2): 256-267.
  2. Y. Dong, Y. Tang, J. Chollet, H. Matile, S. Wittlin, S.A. Charman, W.N. Charman, J.S. Tomas, C. Scheurer, C. Snyder, B. Scorneaux, S. Bajpai, S. Alexander, X. Wang, M. Padmanilayam, S. Cheruku, R. Brun, J. Vennerstrom. Effect of functional group polarity on the antimalarial activity of sprio and dispiro-1,2,4-trioxolanes. (2006) Bioorganic & Medicinal Chemistry, 14: 6368-6382.
  3. L. Sek, B. J. Boyd, W.N. Charman and C.J.H. Porter. Examination of the impact of a range of pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of pipidic formulations of atovaquone. (2006) Journal of Pharmacy and Pharmacology, 58: 809-820
  4. R. Holm, T. Porsgaard, C.J.H. Porter, C.E. Hoy, G.A. Edwards, A. Mullertz, H. Kristensen and W.N. Charman. Lymphatic fatty acids in canines dosed with pharmaceutical formulations containing structured triacyglycerols. (2006) European Journal of Lipid Science and Technology, 108: 714-722.
  5. M. Padmanilayam, B. Scorneaux, Y. Dong, J. Chollet, H. Matile, S. A. Charman, D. Creek, W.N. Charman, J.S. Tomas, C. Scheurer, S. Wittlin, R. Brun, and J. Vennerstrom. Antimalarial activity of N-Alkyl amine, carboxamide, sulphonamide, and urea derivatives of a dispiro-1,2,4-trioxolane piperdine. (2006) Bioorganic and Medicinal Chemistry Letters, 16: 5542-5545. 
  6. N.L. Leveque, W.N. Charman and F.C.K. Chiu. Sensitive method for the quantitative determination of proguanil and its metabolites in rat blood and plasma by liquid chromatography-mass spectrometry. (2006) J. Chromatography B, 830: 314-321.
  7. C.S. Perry, S.A. Charman, R.J. Prankerd, F.C.K. Chiu, M.J. Scanlon, D. Chalmers and W.N. Charman. The binding interaction of synthetic ozonide antimalarials with natural and modified beta-cyclodextrins. (2006) J. Pharm. Sci., 95, 146-158.
  8. S.A. Charman, C.S. Perry, F.C.K. Chiu, K.A. McIntosh and W.N. Charman. Alteration of the pharmacokinetics of a new chemical entity in the presence of a substituted cyclodextrin. (2006) J. Pharm. Sci. 95: 256-267.
  9. C.S. Perry, S.A. Charman, R.J. Prankerd, F.C.K. Chiu, Y. Dong, J.L. Vennerstrom and W.N. Charman. Chemical kinetics and aqueous degradation pathways of a new class of synthetic ozonide antimalarials. (2006) J. Pharm. Sci., 95: 737-747.
  10. N.L. Trevaskis, C.J.H. Porter and W.N. Charman. The lymph lipid precursor pool is a key determinate of intestinal lymphatic drug transport. (2006) J. Pharmacol. Exp. Ther., 316: 881-891.
  11. N. Trevaskis, P. Tso, T. Rider, W.N. Charman, C.J.H. Porter, R. Jandacek. Tissue uptake of DDT is independent of chylomicron metabolism. (2005) Archives in Toxicology  (In press)
  12. N.L. Leveque, W.N. Charman and F.C.K. Chiu. Sensitive method for the quantitative determination of proguanil and its metabolites in rat blood and plasma by liquid chromatography. Journal of Chromatography B (2005) 830: 314-321.
  13. N. Trevaskis, C.J.H. Porter and W.N. Charman. Bile increases intestinal lymphatic drug transport in the fasted rat. (2005) Pharmaceutical Research, 22(11): 1863-1870. 
  14. T. Velkov, S. Chuang, J. Wielens, H, Sakellaris, W. N. Charman, C.J.H. Porter and M. Scanlon.  The Interaction of Lipophilic Drugs with Intestinal Fatty Acid-Binding Protein. (2005) The Journal of Biological Chemistry, 280 (18): 17766 - 17769.
  15. Y. Dong,  J. Chollet,  H. Matile, S.A. Charman, F. Chiu,  W.N. Charman, B. Scorneaux, H. Urwyler, J. Santo Tomas, C. Scheurer, A.D. Snyder, X. Wang, J. Karle, Y. Tang, S. Wittlin, R. Brun, J. Vennerstrom.  Spiro and Dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes. (2005) J. Med. Chem. 48: 4953-4961.
  16. D.J. Creek, F. Chiu, R. Prankerd, S.A. Charman, W.N. Charman. Kinetics of iron-mediated artemisinin degradation: effect of solvent composition and iron salt.(2005) J. Pharm. Sci. 94: 1820-1829.
  17. G.A. Kossena, W.N. Charman, B.J. Boyd, C.J.H. Porter.  Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug (2005) J. Pharm. Res. 94(3): 481-492. 
  18. J.L.Vennerstrom, S. Arbe-Barnes, R. Brun, S.A. Charman, F.C.K. Chiu, J. Chollet, Y. Dong, A. Dorn, D. Hunziker, H. Matile, K.A. McIntosh, M. Padmanilayam, J. Santo Tomas, C. Scheurer, B. Scorneaux, Y. Tang, H. Urwyler, S. Wittlin, W.N. Charman. Identification of an antimalarial synthetic trioxolane drug development candidate.(2004) Nature, 430: 900-904.
  19. C.J.H. Porter, A.M. Kaukonen, B.J. Boyd, G.A. Edwards,  W.N. Charman.Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol administered as a medium-chain lipid-based microemulsion formulation. (2004) Pharm. Res., 21: 1405-1412.
  20. G.A. Kossena, W.N. Charman, B.J. Boyd, C.J.H. Porter. A novel cubic phase of medium chain formulation lipid origin for the delivery of poorly water soluble drugs.(2004) J. Controlled Release, 99: 217-229.
  21. M.P. McIntosh, A.J. Batey, S.J. Coker, C.J.H. Porter, W.N. Charman.Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anesthetised rabbit model. (2004) J. Pharm. Pharmacol., 56: 69-77.
  22. G.A. Kossena, W.N. Charman, B.J. Boyd, D.E. Dunstan, C.J.H. Porter.Probing drug solubilisation patterns in the gastrointestinal tract after administration of lipid based delivery systems: A phase diagram approach. (2004) J. Pharm. Sci., 93:332-348.
  23. A.M. Kaukonen, B.J. Boyd, W.N. Charman, C.J.H. Porter. Drug solubilisation behaviour during in vitro digestion of suspension formulations of poorly water soluble drugs in triglyceride lipids. (2004) Pharm. Res., 21:254-260.
  24. S-M Khoo, D.M. Shackleford, C.J.H. Porter, G.A. Edwards, W.N. Charman. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit dose lipid-based formulation to fasted dogs. (2003) Pharm. Res., 20:1460-1465.
  25. D.M. Shackleford, W.A. Fassen, N. Houwing, H. Lass, G.A. Edwards, C.J.H. Porter, W.N. Charman. The contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two Andriol formulations in conscious lymph-duct cannulated dogs (2003) J. Pharmacol. Exp. Ther., 306:925-933.
  26. B.M. Johnson, W.N. Charman, C.J.H. Porter. Application of compartmental modelling to an examination of in vitro permeability data: Assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. (2003) Drug Metab. Dispos., 31:1151-1160.
  27. B.M. Johnson, W. Chen, R.T. Borchardt, W.N. Charman, C.J.H. Porter. A kinetic evaluation of the absorption, efflux and metabolism of verapamil in the autoperfused rat jejunum. (2003) J. Pharmacol. Exp. Ther., 305:151-158.
  28. G.A. Kossena, B.J. Boyd, C.J.H. Porter, W.N Charman. Separation and characterisation of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. (2003) J. Pharm. Sci., 92: 634-648.
  29. L. Sek, C.J.H. Porter, A.M. Kaukonen, W.N. Charman. Evaluation of the in vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. (2002) J. Pharm. Pharmacol., 54:29-41.
  30. S-M Khoo, R.J. Prankerd, G.A. Edwards, C.J.H. Porter, W.N. Charman. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after post-prandial administration to dogs.(2002). J. Pharm. Sci., 91:647-659. 
  31. S-M Khoo, G.A. Edwards, C.J.H. Porter, W.N. Charman. A conscious dog model for assessing the absorption, enterocyte-based metabolism and intestinal lymphatic transport of halofantrine.(2001) J. Pharm. Sci., 90:1599-1607.
  32. W.N. Charman. Lipids, lipophilic drugs, and oral drug delivery - some emerging concepts.(2000)   J. Pharm. Sci., 89: 967-978.